-
1تقرير
المصدر: A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03907488Test
-
2تقرير
المؤلفون: National Cancer Institute (NCI)
المصدر: A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03712202Test
-
3تقرير
المساهمون: Jane N. Winter, Jane N. Winter, M.D.
المصدر: Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03077828Test
-
4تقرير
المصدر: A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00381940Test
-
5تقرير
المساهمون: Jane N. Winter, Principal Investigator
المصدر: Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03226249Test
-
6تقرير
المؤلفون: National Cancer Institute (NCI)
المصدر: A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00025259Test
-
7تقرير
المصدر: A Phase II Study of PS-341 (Bortezomib) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00082966Test
-
8تقرير
المصدر: A Phase I/II Study of Flavopiridol Administered as a 30-Minute Bolus Followed by a 4-Hour Infusion in Lymphomas and Multiple Myeloma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00112723Test
-
9تقرير
المصدر: A Phase II Trial of Suberoylanilide Hydroxamic Acid (NSC-701852) for Recurrent or Primary Refractory Hodgkin's Lymphoma
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00132028Test
-
10تقرير
المؤلفون: National Cancer Institute (NCI)
المصدر: A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease
الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT00302003Test
Other URLs: https://nctn-data-archive.nci.nih.govTest/